Bionano will host a webinar featuring the study’s lead author, Dr. Guilin Tang, who will discuss the study and its findings in detail, including a summary of the potential implications for wide-spread ...

Objective: Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with various clinical features influencing its prognosis. The aim of this study to evaluate the impact of ...

Bionano will host a webinar featuring the study's lead author, Dr. Guilin Tang, who will discuss the study and its findings in detail, including a summary of the potential implications ...

Researchers identified ten ferroptosis-related lncRNAs associated with AML prognosis. These lncRNAs were used to construct a prognostic model, effectively predicting patient survival. High-risk ...

and poor prognosis compared to subjects with no detectable CAG. Based on the OGM findings, clinical researchers found higher than anticipated rates of CAG in AML (16% of cases overall and ...

Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive ...

The FLT3 mutation is expressed in about 30% of AML patients and is associated with a worse prognosis, higher relapse rate, faster progression and shorter overall survival, and FLT3 inhibitors have ...